DOCSLIB.ORG

Extended Version . This Link Downloads a File

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Published by: IDIBAPS Rosselló, 149-153 08036 Barcelona Editorial board IDIBAPS Scientific Coordination Office Art direction & graphic design Marc Montalà www.marcmontala.com Cover photo © Mar Petit © IDIBAPS 2018 http://creativecommons.org/licenses/by-nc-sa/4.0/ ANNUAL SCIENTIFIC REPORT 2017 INDEX 08 Foreword IDIBAPS About IDIBAPS Staff Research and innovation outputs Funding Scientific facilities Institutional projects Training Communications and public engagement News 50 Area 1 Biological aggression and response mechanisms 88 Area 2 Respiratory, cardiovascular and renal pathobiology and bioengineering 138 Area 3 Liver, digestive system and metabolism 202 Area 4 Clinical and experimental neuroscience 258 Area 5 Oncology and haematology 314 Transversal research groups 325 Team and group leaders index ANNUAL SCIENTIFIC REPORT 2017 FOREWORD IDIBAPS © Joan Mir About IDIBAPS The Institut d’Investigacions Additionally, 3 transversal groups perform Biomèdiques August Pi i Sunyer research in Primary Care, Nursing, (IDIBAPS) is a biomedical research Pharmacology and Clinical Trials. institute of excellence. It combines clinical and basic research in order to accelerate Scientific breakthroughs are never the result the translation of the knowledge to the of chance. They are the fruit of long-term benefit of the patients. IDIBAPS is a commitments that involve not only CERCA (Research Centers of Catalonia) researchers, but also society as a whole. center and was first accredited as Instituto de Investigación Sanitaria (Instituto de IDIBAPS is a consortium that has made such Salud Carlos III) in 2009. a commitment, to encourage translational research, innovation and technological Founded in 1996, it is a public consortium progress in the field of biomedicine, through formed by the Generalitat de Catalunya, different programmes addressing diseases Hospital Clínic de Barcelona, Faculty of with a high prevalence, morbidity and mortality Medicine and Health Sciences of the in our society. University of Barcelona and, as an associated partner, the CSIC’s Barcelona Biomedical The data presented in this Annual Scientific Research Institute. Report details the ever-growing scientific achievements made by IDIBAPS investigators The Fundació Clínic per a la Recerca and their capacity for attracting public and Biomèdica (FCRB) is a key institution to private funding. This enormous potential for understand the functioning of IDIBAPS as a capturing resources and their translation into whole. It is a non-profit foundation that applied results for clinical practice constitute provides researchers with administrative and the best guarantee for securing the future of management support. The IDIBAPS research the Institute and its impact on society and community is composed of more than 1,500 industry. people, grouped into 107 research groups organized across 5 different areas of knowledge. AREA 1 Biological aggression and response mechanisms AREA 2 Respiratory, cardiovascular and renal pathobiology and bioengineering AREA 3 Liver, digestive system and metabolism AREA 4 Clinical and experimental neuroscience AREA 5 Oncology and haematology 9 FOREWORD IDIBAPS Organisation chart IDIBAPS requires a solid administrative infrastructure to support the state-of-the-art research developed by its researchers. For this reason, IDIBAPS works together with the Fundació Clínic per a la Recerca Biomèdica (FCRB) to ensure efficiency and quality in the services offered to its research staff, in particular, in the areas of research project management and administration. Elías Campo, MD PhD Marga Nadal, PhD Rosa Vilavella Director of IDIBAPS and of FCRB Director of Strategy General Manager Gemma Pedrola Arantxa Fernández Laura Lopera Secretary Secretary Secretary [email protected] [email protected] [email protected] T. +34 93 312 94 11 T.+34 93 227 18 30 T. +34 93 227 18 42 CEK, mezzanine floor CEK, mezzanine floor CEK, mezzanine floor Gemma Llaverías Marta Fernández Head of the Scientific Head of the Human Resources Office Coordination Office Sònia Meléndez Elisenda Vendrell Head of the Accounting and Finance Office Head of the KTT Office Ernest Costa Daniel Arbós Head of the TIC Office Head of the Communication Office Juan Suero Gemma Pascual Head of the Purchasing Head of the Institutional Actions Office and General Services Office Sandra Piquer Guillem Masdeu Coordinator of IDIBAPS laboratories Head of the Legal Office Anna Bosch RESEARCH MANAGEMENT OFFICE Head of IDIBAPS core facilities Sandra Pérez and Biobank coordinator Head of the Pre-Award Office for National Grants Maria Carol Head of the Pre-Award Office for International Grants Judit Martínez Head of the Post-award Grants Office 10 Governance and structure Governance is exercised through the following boards and committees: THE BOARD OF GOVERNORS THE SCIENTIFIC ADVISORY BOARD Miguel Ángel del Pozo Centro Nacional de Investigaciones Conformed by representatives of the External leading scientists chosen by the Cardiovasculares(CNIC), Madrid different institutions of the consortium, Board of Governors, compose this board supervises IDIBAPS actions, budget and to advise IDIBAPS on the different Ciril Rozman results. Its mission is to take scientific scientific issues affecting its activities. Hospital Clínic de Barcelona, decisions in consultation with the These leading scientists have in-depth Universitat de Barcelona Scientific Advisory Board, and to evaluate knowledge of the Spanish, European the implementation of the strategic plan. and/or American R+D+I systems as they Jesús San Miguel hold positions in prestigious research Hospital Clínico de Salamanca CHAIRMAN institutions. Francesc Subirada Francisco Sánchez-Madrid General Director, Direcció General de CHAIRMAN Hospital La Princesa, Madrid Recerca, Departament d’ Empresa i Jesús Ávila Coneixement. Generalitat de Catalunya Centro de Biología Molecular Eugenio Santos Severo Ochoa (CBM), Madrid Centro de Investigación del Cáncer (CIC), VICE-CHAIRMAN Salamanca José Carlos Fernández Checa BOARD MEMBERS Director, Instituto de Investigaciones Fernando Arenzana-Seisdedos Antonio Vidal-Puig Biomédicas de Barcelona (IIBB-CSIC) Institut Pasteur, Shangai, China School of Clinical Medicine, University of Cambridge, UK BOARD MEMBERS Bartolomé Celli Albert Barberà Harvard University, Cambridge, UK General Director, Direcció General de Recerca I Innovació en Salut, Departament Francisco Fernández Avilés de Salut, Generalitat de Catalunya Hospital Gregorio Marañón, Madrid Domènec Espriu Guadalupe García-Tsao Research Vice-Dean, Universitat de Barcelona Yale Liver Center, New Haven, US Lluís Calvo Ramon Gomis Institutional Coordinator, Consejo Superior de IDIBAPS, Barcelona Investigaciones Científicas (CSIC) in Catalonia Roberto Groszmann Francesc Cardellach Yale University School of Medicine, Dean of the School of Medicine, Universitat de West Haven, US Barcelona José López Barneo Elías Campo Instituto de Biomedicina de Sevilla (IBiS) Director, IDIBAPS Carlos López Otín Josep Maria Campistol Universidad de Oviedo General Manager, Hospital Clínic de Barcelona Carlos Macaya Antoni Castells Hospital Clínico San Carlos, Madrid Medical Director, Hospital Clínic de Barcelona Óscar Marín SECRETARY King's College London, UK Lluís Rovira Director, CERCA José M. Mato Centro de Investigación Cooperativa en Biociencias (CIC bioGUNE), Bizcaya Federico Mayor Centro de Biología Molecular Severo Ochoa, Madrid Angel Pellicer NYU School of Medicine, New York, US 11 FOREWORD IDIBAPS THE STEERING COMMITTEE THE INTERNAL ADVISORY COMMITTEE GUEST MEMBERS Montserrat Batlle Which is responsible for the supervision IDIBAPS researchers representing all Works Committee President of the progress achieved by the five research areas advise the IDIBAPS director IDIBAPS research areas, the recruitment to implement the strategic decisions taken Jaume Bosch of new scientists within the framework of by the Board of Governors. Researcher different research programmes, and the Hepatic hemodynamics and portal hypertension evaluation of IDIBAPS training CHAIRMAN programmes. Elías Campo Francesc Cardellach Director Dean of the School of Medicine CHAIRMAN Universitat de Barcelona Elías Campo STEERING COMMITTEE REPRESENTATIVES Director Josep Maria Llovet Fàtima Crispi Group Leader Researcher MEMBERS Translational research in hepatic oncology Fetal and perinatal medicine Neus Agell Vice-Dean of School of Medicine Joan Carles García-Pagán José Carlos Fernández-Checa and Health Sciences Group Leader Director Universitat de Barcelona Hepatic hemodynamics and portal hypertension Instituto de Investigaciones Biomédicas de Research Deputy Director Barcelona (IIBB-CSIC) Cristina Fillat Hospital Clínic de Barcelona Group Leader Josep M. Gatell Gene therapy and cancer INSTITUTIONAL REPRESENTATIVES National Coordinator of the RETIC on AIDS Joan Cid Joan Carles García-Pagán Physicians’ Representatives Francesc Graus Group Leader Hospital Clínic de Barcelona Cellex building representative Hepatic hemodynamics and portal hypertension Research Deputy Director Guadalupe Mengod Anna Novials Hospital Clínic de Barcelona Deputy Director Group Leader Instituto de Investigaciones Biomédicas Pathogenesis and prevention of diabetes Josep Maria Llovet de Barcelona (IIBB-CSIC) Group Leader Carmen Peralta Translational research in hepatic oncology AREA REPRESENTATIVES Group Leader AREA 1 Liver transplantation and graft viability Anna Planas Josep Maria Miró, Coordinator Coordinator of the IDIBAPS Research Area 4 Maria Cinta Cid, Representative
Recommended publications
  • En Som Hereus 25 Copes D'europa Les Claus De L'èxit

    En Som Hereus 25 Copes D'europa Les Claus De L'èxit

    BARÇA Revista Oficial FC Barcelona · Juny 2005 Nº15 · 3 Euros www.fcbarcelona.com ELEL TRIOMFTRIOMF DEDE LALA IL·LUSIÓIL·LUSIÓ En som hereus 25 copes d’Europa Les claus de l’èxit El fil de l’èxit, lliga El Barça arrodoneix l’èxit Han treballat amb l’equip a lliga, en una foto amb els títols continentals campió de la lliga i ara històrica de l’hoquei i I’handbol l’analitzen des de dins EDITORIAL El repte de JUNY DEL 2005 la continuïtat Edita: Futbol Club Barcelona ls números es poden fer de mil maneres diferents i encara es poden llegir de moltes Av.d’Arístides Maillol s/n - 08028 Barcelona més. Tanmateix, si es tracta de fer-los i d’interpretar-los honestament només n’hi Tlf. 9021899 00 - Fax 934112210 Eha una. En aquest cas, el resultat final ens ha de donar un disset. La Lliga espan- Direcció electrònica: [email protected] yola que el primer equip de futbol ha aconseguit aquesta temporada és la que fa disset en la història del FC Barcelona. Arribar a aquest resultat no és debades perquè converteix l’ac- Director: Jordi Badia tual plantilla campiona en hereva de les setze plantilles que un dia també la van guanyar. De Samitier a Ronaldinho, d’Arocha a Eto’o, o de Platko a Valdés; dels herois d’ahir –els Subdirectors: Antoni Aira, Toni Ruiz de la primera lliga, la del 1928-29–, als herois d’avui. I aquests èxits sempre s’han lligat i Eduard Pujol amb el fil blaugrana de la ferma voluntat de pervivència.
  • Pathogenetic Mechanisms in Vascular Dementia

    Pathogenetic Mechanisms in Vascular Dementia

    lnt J Clin Lab Res 24: 15-22, 1994 Springer-Verlag 1994 Pathogenetie mechanisms in vascular dementia Lueilla Parnetti 1, Daniela Mari 2, Patrizia Mecocci 1, and Umberto Senin 1 1 Sezione di Gerontologia e Geriatria, Dipartimento di Medicina Clinica, Patologia e Farmacologia, Universitfi degli Studi di Perugia, Via Eugubina 42, 1-06122 Perugia, Italy 2 Istituto di Medicina Interna, UniversitY. degli Studi di Milano, Milan, Italy Summary. Vascular dementia accounts for approximately figures reach and surpass prevalence rates for DAT [62]. 20% of all cases of dementia and for about 50% in VD is the commonest cause of dementia in Japan, being subjects over 80 years. Thromboembolism with multiple responsible for up to 50% of all clinical cases and for cerebral infarcts was considered to be almost the only 54%-65% of all autopsy-confirmed dementias world- pathogenetic pathway of vascular dementia, with multi- wide [88]. While degenerative dementias are currently un- infarct dementia as its clinical manifestation. However, treatable, there is, in contrast, a definite potential for the there is a great heterogeneity of vascular dementia syn- prevention and treatment of cerebrovascular diseases. dromes and pathological subtypes, as documented by the The varied clinical presentations and the multiple number of pathogenetic mechanisms now known to un- causes of dementia syndrome make clinical diagnosis derlie the clinical picture. They include thromboem- quite difficult. In 1984, a Work Group on the Diagnosis bolism and extracerebral and cerebral factors. Among of Alzheimer's Disease established by the National Insti- the extracerebral factors are ischemic hypoxic dementia tute of Neurological and Communicative Disorders and (i.e., dementia due to hypoperfusion), vasculitis, hyper- Stroke and the Alzheimer's Disease and Related Disor- viscosity and abnormalities of hemostasis.
  • Pdf Butlletí 2008

    Pdf Butlletí 2008

    BOLETÍN DE LA SOCIEDAD CASTELLONENSE DE CVLTVRA BOLETÍN de la SOCIEDAD CASTELLONENSE DE CVLTVRA TOMO LXXXIV 2008 REFLEXIONS CORELLANES. A PROPÒSIT D’UN LLIBRE SOBRE LA LITERATURA... 5 DE LA SOCIEDAD CASTELLONENSE DE CVLTVRA Tomo LXXXIV • Enero-Junio 2008 • Cuad. I-II Reflexions corellanes. A propòsit d’un llibre sobre la literatura i l’espiritualitat de Corella 1. L’any 2007 la Institució Alfons el Magnànim, de la Diputació de València, publicava Literatura i espiritualitat. Aproximació a l’obra de Corella com a res- posta davant Déu i l’home, una obra valenta i suggerent d’Antoni López Quiles, un bon coneixedor de la literatura corellana i de l’espiritualitat. Efectivament, l’autor ha dedicat esforços a la redacció de treballs sobre el llenguatge bíblic i litúrgic, so- bre les relacions sovint complexes entre l’Església i la nostra llengua i cultura, i sobre altres aspectes filològics i literaris; també –és molt il·lustratiu– va editar fa anys el Salteri de Corella. Atesos els antecedents, ja podíem suposar que hi troba- ríem pàgines d’aquelles que, si més no, inviten a la reflexió. Els impulsos inicials d’aquest llibre són ben definits per López Quiles a la In- troducció. Ens hi parla del desfici que li produïa la insistència de la crítica a negar un altre valor que el literari a l’obra corellana, sobretot quan observava, a sota de l’expressió, possibles propostes, pensaments, idees, no solament intel·lectuals sinó també socials, morals i religioses. Per a ell, Corella responia «a les interpel·lacions del moment històric que li toca viure» (p.14) Benvolgut desfici, doncs, el de López perquè ens ha proporcionat unes pàgines interessants sobre la literatura i –molt prin- cipalment– sobre la religiositat de Roís de Corella.
  • Actos De BARCELONA Del BORME Núm. 133 De 2011

    Actos De BARCELONA Del BORME Núm. 133 De 2011

    BOLETÍN OFICIAL DEL REGISTRO MERCANTIL Núm. 133 Miércoles 13 de julio de 2011 Pág. 35472 SECCIÓN PRIMERA Empresarios Actos inscritos BARCELONA 293800 - CAIXABANK SA. Nombramientos. APODERADO: ALVAREZ-RENDUELES VILLAR IGNACIO;COLL ESCURSELL FRANCESC XAVIER;DE CONRADO Y VILLALONGA JOSE FRANCISCO;DURAN MONTOLIO ELISA MARIA;LEPORACE ROIG ROBERTO;LLUCH MARTIN VICTORINO;MARTINEZ PERALES BIBIANO MANUEL;MUGURUZA ANGULO JUAN JOSE;OROZCO MUÑOZ ANDRES;REGUERA DIAZ JUAN;ROMERA GOMEZ MANUEL;SASTRE PAPIOL SEBASTIAN;VILAR BARRABEIG JOAQUIN;ALEGRE DE MIQUEL IGNACIO;ESCOLANO CEBOLLA JESUS;FABREGA CARDELUS JUAN;FUERTES BLASCO JUAN RAMON;GALLEGO GONZALEZ JUAN CARLOS;GARCIA BRAGADO DALMAU ALEJANDRO;GIRO RIBAS JAIME;LANASPA GATNAU JAIME. Datos registrales. T 42657 , F 50, S 8, H B 41232, I/A 110 ( 1.07.11). 293801 - CAIXABANK SA. Nombramientos. APODERADO: CAPELLA ALSINA PERE;AGRAMUNT LAMUA RICARDO;ALGANS MAS TERESA;ALLENDE FERNANDEZ VICTOR MANUEL;ALONSO FELIPE JESUS LORENZO;ALVAREZ GARCIA JUAN ALFONSO;ARCE SAEZ FERNANDO;BADIOLA GOMEZ IGNACIO;BADIOLA URIARTE JUAN PEDRO;BALLBE BELLERA JOSE;BARRACHINA PICO MANUEL;BENHAMOU GALLEGO MARC ARTHUR;BERMEJO BARRERA JUAN MANUEL;BILBAO KAMIO JOSE MANUEL;BRAVO MONTESINOS TOMAS;BUSTILLO MARTINEZ ALFREDO;BUXARRAIS ESTRADA VICENC;CABALLE BENEJAM LLUIS;CABANAS GODINO LUIS;CABANILLAS MORENO JULIAN;CALDERON DE OYA OSCAR;CAPELLA PIFARRE NATIVIDAD PILAR;CARPIO GARIJO OSCAR VALENTIN;CARRERA BONADONA PERE LLUIS;CASANOVAS DOSRIUS CARLOS;CATALA BUERA MARIA JESUS;CEBRIAN TORALLAS JUAN;COMPTE PRATS JOSE LUIS;CORNEJO CASTILLO FRANCISCO;COSTA
  • Intracranial Angioplasty & Stenting

    Intracranial Angioplasty & Stenting

    Position Statement Intracranial Angioplasty & Stenting for Cerebral Atherosclerosis: A Position Statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology Stroke is the third leading cause of death and the 20) with the definitive National Institutes of Health leading cause of adult disability in North America, (NIH) study demonstrating a first year ischemic Europe, and Asia (1, 2). Intracranial cerebral athero- stroke rate in the pertinent vascular territory of at sclerosis accounts for approximately 8–10% of all least 11% (17). ischemic strokes with a higher reported incidence in the Asian, African, and Hispanic descent populations (3–5). Risk factors include insulin-dependent diabe- Review of Studies tes mellitus, hypercholesterolemia, hypertension, and Surgical Revascularization—EC/IC Bypass Trial cigarette smoking (6–8). In the United States, it is (Extracranial to Intracranial): In 1985, the EC/IC By- estimated that 40,000–60,000 new strokes per year pass Study Group published the results of a trial that are due to intracranial cerebral atherosclerosis. attempted to prove benefit for a surgical approach to treating intracranial atherosclerotic stenoses or occlu- Intracranial Atherosclerosis sion (18). This extracranial to intracranial arterial bypass trial was a prospective, multicenter, interna- Etiology tional study involving 1377 patients and attempted to Four mechanisms for ischemic stroke secondary to show that patients with an intracranial atherosclerotic intracranial atherosclerosis have been proposed: (1) stenosis or occlusion could benefit by an EC/IC by- hypoperfusion; (2) thrombosis at the site of stenosis pass. This trial failed for all subgroups, and in partic- due to plaque rupture, intraplaque hemorrhage, or ular for those with middle cerebral artery stenosis.
  • Diagnostic and Therapeutic Approach of Carotid and Cerebrovascular Plaque on the Basis of Vessel Imaging

    Diagnostic and Therapeutic Approach of Carotid and Cerebrovascular Plaque on the Basis of Vessel Imaging

    Review J Lipid Atheroscler 2017 June;6(1):15-21 https://doi.org/10.12997/jla.2017.6.1.15 JLA pISSN 2287-2892 • eISSN 2288-2561 Diagnostic and Therapeutic Approach of Carotid and Cerebrovascular Plaque on the Basis of Vessel Imaging Dong Hyun Lee, Jong-Ho Park Department of Stroke Neurology, Seonam University Myongji Hospital, Goyang-si, Korea Atherosclerosis, characterized by chronic systemic inflammation with plaque formation, is one of the major causes of cerebrovascular disease. Recent advances in imaging technologies can help further understand the overall process and biology of plaque formation and rupture. Thus, these imaging techniques could aid clinicians to make better decision for risk stratification, therapeutic planning, and prediction of future cerebrovascular event. Ultrasonography, magnetic resonance imaging, and positron emission tomography are the rapidly-evolving imaging modalities dealing with assessment of atherosclerotic plaque. By advances in imaging technology for evaluating plaque, we can characterize the vulnerability of plaque in-vivo, understand the composition and activity of plaque, assess therapeutic response to treatment, and ultimately predict the overall risk of future cerebrovascular episodes. In this review, we will introduce current understanding of various advanced imaging modalities and clinical application of these imaging technologies. (J Lipid Atheroscler 2017 June;6(1):15-21) Key Words: Atherosclerosis, Plaque, Imaging, Carotid artery disease, Cerebrovascular disease INTRODUCTION vascular episodes, and reliably monitor the therapeutic response to medication. Atherosclerosis is a chronic systemic inflammatory Recent advances in imaging technologies can help disease with an insidious process caused by multiple further understand the overall process in atherosclerosis pathological changes triggering lipoprotein dysregulation including molecular biology of plaque formation and and immunocyte activation within the arterial system.1 rupture.
  • Stuart Bird of S/Y Phryne Has Chosen Marina Port Vell As His Home Port

    Stuart Bird of S/Y Phryne Has Chosen Marina Port Vell As His Home Port

    A TRIBUTE TO F1 ISSUE 02 SPRING 2014 LEGACY OF LUXURY A classic Ferrari takes on Fashion trends from the Barcelona’s historic Montjuïc Park sisters behind Carmina Rotger CITY OF COLOUR BUSINESS AND PLEASURE Escofet brings its unique The port of Barcelona is a architectural vision to MPV vibrant ecosystem for business ISSUE 02 2014 WELCOME A superyacht hub in the Well, what an amazing six months it has been since we launched the first edition of Superyacht Barcelona. Spain has repealed the matriculation tax – a tax on charter vessels – that did so much to inhibit the growth heart of the city of the region as a charter yacht destination. And the city of Barcelona has joined the port authorities and a raft of other business to sign the Nautical Cluster Charter – creating an independent body, chaired by local entrepreneur Tony Tió, to foster growth in the maritime economy. At the same time, three years of expensive and technically complex work has succeeded in transforming Marina Port Vell – just 15 minutes walk from Passeig de Gràcia in the heart of Barcelona – into a five-star home port for superyachts. The collective goal of the Nautical Cluster signatories is to reposition Barcelona as the number one maritime destination in Published by The Superyacht Agency Many thanks to our contributors: Email: [email protected] Jethro Bovingdon, Erik Brown, Vera Celia, Europe – and we’re well on the way. Meanwhile, the city www.thesuperyachtagency.com Miguel Delaney, Don Hoyt Gorman, Pascal Harter, of Barcelona – the largest metropolis on the Kate Hubert, Graham Keeley, Cathal Morrow, Editor: Lauren Barker / Erik Brown Rachel Syers and Will Mathieson.
  • Albert Ferrer, Recluta Lleva Dos Semanas De Mili Y Se Perderá El Bélgica-Espáña Porque Ese Día Jura Bandera

    Albert Ferrer, Recluta Lleva Dos Semanas De Mili Y Se Perderá El Bélgica-Espáña Porque Ese Día Jura Bandera

    • . _______________ azulDIrnn.. .1 .:.. • :.., :, ..‘,. Albert Ferrer, recluta Lleva dos semanas de mili y se perderá el Bélgica-Espáña porque ese día jura bandera JOAN POQUÍ/TOMÁS GUASCH. BARCELONA lbert Ferrer lleva quince días de mili. Desde el pasado A día 14, enqueseincorporóafilas, el’Chapi’esreclu •ta del acuartelamiento de Sant Climent de Sescebes. Aunque hasta ahora sus deberes militares han pasado desa percibidos, puesto que no le han impedido seguir con su ac tividad normal, podrían hacerle perder algún compromiso 6 deportivo importante. No podrá jugar el Bélgica-España del 17 de diciembre porque ese día jura bandera. lateral El barcelonista, que ayer no participó junto a sus compañeros en el entrenamiento matinal por estar cum pliendo con su instrucción en Sant Climent, es actualmente ______ Ma beneficiario de la ley que permite a los deportistas de elite 29NOV hacer una mili ‘light’. El Estado considera que, a través de su 1994 prestación en la alta competición internacional, los deportis tas de alto nivel cumplen ya - con un servicio suficiente al país, al ejercer una represen- E/latera! goza de la tación de España fuera de los límites estatales. consideracion de Hay una serie de obli deportista de elite, gaciones ineludibles, sin - bargo, que Albert Ferrer que le permite debe cumplir: Entre ellas prestar un servicio está la jura de bandera, que ,,. , tendrá lugar en Sant Climent ¡igi it próximo el 17 de diciembre. Ferrer, uno de los fijos en la selección de Javier Clemente, se perderá, con total seguri dad, el Bélgica-España de ese mismo día, puesto que deberá Ferrer guai-da el secreto • Ayer fu e primer dí que no entrené, por lo que su mili no ha trasCendido • FOTO: EMD permanecer en Sant Climent, junto a sus compañeros de ‘quinta’, entre el 12 y el 17 del mes próximo de forma iriexcu sable.
  • Search for Reliable Circulating Biomarkers to Predict Carotid Plaque Vulnerability

    Search for Reliable Circulating Biomarkers to Predict Carotid Plaque Vulnerability

    International Journal of Molecular Sciences Review Search for Reliable Circulating Biomarkers to Predict Carotid Plaque Vulnerability Núria Puig 1,2, Elena Jiménez-Xarrié 3,*, Pol Camps-Renom 3,* and Sonia Benitez 2,* 1 Department of Biochemistry and Molecular Biology, Faculty of Medicine, Building M, Autonomous University of Barcelona (UAB), 08193 Cerdanyola del Vallès, Barcelona, Spain; [email protected] 2 Cardiovascular Biochemistry, Biomedical Research Institute Sant Pau (IIB-Sant Pau), 08041 Barcelona, Spain 3 Stroke Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), 08041 Barcelona, Spain * Correspondence: [email protected] (E.J.-X.); [email protected] (P.C.-R.); [email protected] (S.B.); Tel.: +34-93-553-7595 (S.B.) Received: 2 October 2020; Accepted: 1 November 2020; Published: 3 November 2020 Abstract: Atherosclerosis is responsible for 20% of ischemic strokes, and the plaques from the internal carotid artery the most frequently involved. Lipoproteins play a key role in carotid atherosclerosis since lipid accumulation contributes to plaque progression and chronic inflammation, both factors leading to plaque vulnerability. Carotid revascularization to prevent future vascular events is reasonable in some patients with high-grade carotid stenosis. However, the degree of stenosis alone is not sufficient to decide upon the best clinical management in some situations. In this context, it is essential to further characterize plaque vulnerability, according to specific characteristics (lipid-rich core, fibrous cap thinning, intraplaque hemorrhage). Although these features can be partly detected by imaging techniques, identifying carotid plaque vulnerability is still challenging. Therefore, the study of circulating biomarkers could provide adjunctive criteria to predict the risk of atherothrombotic stroke.
  • Actos De BARCELONA Del BORME Núm. 131 De 2011

    Actos De BARCELONA Del BORME Núm. 131 De 2011

    BOLETÍN OFICIAL DEL REGISTRO MERCANTIL Núm. 131 Lunes 11 de julio de 2011 Pág. 34769 SECCIÓN PRIMERA Empresarios Actos inscritos BARCELONA 290159 - CRITERIA CAIXACORP SA. Ampliación de capital. Suscrito: 374.403.908,00 Euros. Desembolsado: 374.403.908,00 Euros. Resultante Suscrito: 3.737.293.745,00 Euros. Resultante Desembolsado: 3.737.293.745,00 Euros. Datos registrales. T 42657 , F 28, S 8, H B 41232, I/A 108 (30.06.11). 290160 - MICROBANK DE LA CAIXA SA. Revocaciones. SECR.NO CONS: SASTRE PAPIOL SEBASTIAN. CONSEJERO: PINTO RUIZ JOSE JUAN;SASTRE PAPIOL SEBASTIAN;DE CONRADO VILLALONGA JOSE FRANCISCO;NOGUER PLANAS MIGUEL;ROMERA GOMEZ MANUEL. PRESIDENTE: DE CONRADO VILLALONGA JOSE FRANCISCO. VICEPRESIDEN: PINTO RUIZ JOSE JUAN. APODERADO: DE CONRADO VILLALONGA JOSE FRANCISCO. CONSEJERO: REGUERA DIAZ JUAN;MONTSERRAT MIRO JOSE RAMON. APODERADO: DE CONRADO VILLALONGA JOSE FRANCISCO. CONSEJERO: GALLEGO GONZALEZ JUAN CARLOS;LLOBET MARIA MARIA DOLORS;FRANCOIS XAVIER MARIE MIQUEU. Extinción. Datos registrales. T 39943 , F 48, S 8, H B 53468, I/A 649 (30.06.11). 290161 - CRITERIA CAIXACORP SA. Nombramientos. APODERADO: MORENO GUERRERO MIGUEL;MARTINEZ SANCHIS VICENTE;GUILLEN VERA NARCISO;ANGLADA DE ARBIZU SOL;ESPUÑA TURMO JOSE LUIS;FORNS BASCA MAGDALENA;NAVAS MARTIN MARIA LLUISA;PEREZ COTTA SARA;TERCERO CALDERON MIGUEL;MARTINEZ SANCHIS VICENTE;GUILLEN VERA NARCISO;ANGLADA DE ARBIZU SOL;ESPAÑA TURMO JOSE LUIS;FORNS BASCA MAGDALENA;NAVAS MARTIN MARIA LLUISA;PEREZ COTTA SARA;TERCERO CALDERON MIGUEL;CAIXA D'ESTALVIS I PENSIONS DE BARCELONA;ALCALA SANCHEZ
  • VIEW Open Access the Overlap Between Vascular Disease and Alzheimer’S Disease – Lessons from Pathology Johannes Attems1* and Kurt a Jellinger2

    VIEW Open Access the Overlap Between Vascular Disease and Alzheimer’S Disease – Lessons from Pathology Johannes Attems1* and Kurt a Jellinger2

    Attems and Jellinger BMC Medicine 2014, 12:206 http://www.biomedcentral.com/1741-7015/12/206 Vascular risk factors and Alzheimer’s Disease REVIEW Open Access The overlap between vascular disease and Alzheimer’s disease – lessons from pathology Johannes Attems1* and Kurt A Jellinger2 Abstract Recent epidemiological and clinico-pathological data indicate considerable overlap between cerebrovascular disease (CVD) and Alzheimer’s disease (AD) and suggest additive or synergistic effects of both pathologies on cognitive decline. The most frequent vascular pathologies in the aging brain and in AD are cerebral amyloid angiopathy and small vessel disease. Up to 84% of aged subjects show morphological substrates of CVD in addition to AD pathology. AD brains with minor CVD, similar to pure vascular dementia, show subcortical vascular lesions in about two-thirds, while in mixed type dementia (AD plus vascular dementia), multiple larger infarcts are more frequent. Small infarcts in patients with full-blown AD have no impact on cognitive decline but are overwhelmed by the severity of Alzheimer pathology, while in early stages of AD, cerebrovascular lesions may influence and promote cognitive impairment, lowering the threshold for clinically overt dementia. Further studies are warranted to elucidate the many hitherto unanswered questions regarding the overlap between CVD and AD as well as the impact of both CVD and AD pathologies on the development and progression of dementia. Keywords: Alzheimer’s disease, Cerebrovascular lesions, Cerebral amyloid angiopathy, Cognitive impairment, Lacunes, Microinfarcts, Small vessel disease, White matter lesions Introduction risk factors, e.g., atrial fibrillation and congestive heart fail- The interaction between cerebrovascular disease (CVD) ure, have also been linked to the pathogenesis and progres- and Alzheimer’s disease (AD) is a topic of considerable sion of AD and are among the most important modifiable current interest.
  • Use of High-Resolution 3.0-T Magnetic Resonance Imaging to Characterize Atherosclerotic Plaques in Patients with Cerebral Infarction

    Use of High-Resolution 3.0-T Magnetic Resonance Imaging to Characterize Atherosclerotic Plaques in Patients with Cerebral Infarction

    2424 EXPERIMENTAL AND THERAPEUTIC MEDICINE 10: 2424-2428, 2015 Use of high-resolution 3.0-T magnetic resonance imaging to characterize atherosclerotic plaques in patients with cerebral infarction PENG XU1*, LULU LV2*, SHAODONG LI1, HAITAO GE1, YUTAO RONG1, CHUNFENG HU1 and KAI XU1 1Department of Radiology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221006; 2Department of Computed Tomography and Magnetic Resonance Imaging, Xuzhou Central Hospital, Xuzhou, Jiangsu 221009, P.R. China Received November 12, 2014; Accepted September 1, 2015 DOI: 10.3892/etm.2015.2815 Abstract. The present study aimed to evaluate the utility of Introduction high-resolution magnetic resonance imaging (MRI) in the characterization of atherosclerotic plaques in patients with Cerebral atherosclerosis is an important risk factor for ischemic acute and non-acute cerebral infarction. High-resolution MRI stroke, and is the cause of stroke in 8-15% of patients (1). Factors of unilateral stenotic middle cerebral arteries was performed that lead to stroke and that are associated with cerebral artery to evaluate the degree of stenosis, the wall and plaque areas, stenosis include intraluminal embolus, perforating artery occlu- plaque enhancement patterns and lumen remodeling features sion and low perfusion (2). Currently, common techniques used in 15 and 17 patients with acute and non-acute cerebral infarc- for cerebrovascular evaluation include computed tomography tion, respectively. No significant difference was identified in angiography, magnetic resonance angiography (MRA) and the vascular stenosis rate between acute and non-acute patients. digital subtraction angiography (DSA); however, the majority of Overall, plaque eccentricity was observed in 29 patients, these only examine the vascular lumen.